Pfizer (NYSE:PFE) shares declined 1.44% to close at $24.72 on Tuesday, with trading volume surging to 81.9 million shares—more than double the 50-day average of 36.8 million. The sharp selloff followed the company's announcement that its antibody-drug conjugate (ADC) sigvotatug vedotin, acquired through the $43 billion Seagen deal in 2023, failed to meet the primary endpoint of overall survival in a Phase 3 trial for advanced non-squamous non-small cell lung cancer (NSCLC).
Clinical Setback
The study compared sigvotatug vedotin against docetaxel chemotherapy in 703 patients who had received prior treatment. Pfizer reported that while a stronger survival trend was observed in patients who had undergone only one previous line of therapy—representing about two-thirds of the trial population—the overall results did not achieve statistical significance. The drug's target, integrin beta-6 (IB6), is present in approximately 90% of NSCLC tumors, but early biomarker analysis failed to establish a clear correlation between IB6 expression levels and patient response, complicating future trial design.
Pfizer's chief oncology officer, Jeff Legos, acknowledged the need for further analysis, stating, "more work to be done." Dr. Solange Peters, chair of medical oncology and thoracic cancers at Lausanne University Hospital, described the second-line survival benefit as "clinically meaningful."
Market Reaction and Context
The stock's decline contrasted with gains at rival drugmakers: Johnson & Johnson rose 3.37%, and Eli Lilly added 0.45%. The broader S&P 500 also fell 1.44% on the day. Pfizer's notional turnover at the close reached approximately $2.0 billion, underscoring the market's focus on the clinical update. In early premarket trading Wednesday, shares were nearly flat at $24.76, up just 0.16%. The stock remains about 14% below its 52-week high and roughly 7% above its low.
Leerink analyst David Risinger had previously described the study as a "major oncology catalyst" for Pfizer, according to STAT. The drug was a centerpiece of Pfizer's strategy to bolster its oncology pipeline after the COVID-19 vaccine and treatment windfall began to fade.
Pipeline and Financial Outlook
Pfizer is not abandoning the program. The company is testing sigvotatug vedotin in combination with Merck's Keytruda in a first-line advanced lung cancer Phase 3 trial, and exploring combinations with its own PD-1/VEGF bispecific, PF-08634404. Other ADCs in the pipeline include fetrastobart vedotin, now in Phase 3 for lung cancer.
First-quarter 2026 revenue rose 5% to $14.45 billion, with launched and acquired products contributing 22% operational growth. Pfizer maintained its full-year revenue forecast of $59.5 billion to $62.5 billion. However, the company has not conducted any share repurchases in 2026 and does not expect to do so this year, leaving dividends and clinical data as key stock drivers. In Q1, Pfizer paid $2.4 billion in cash dividends.
Upcoming Catalysts
Pfizer's next scheduled update is its second-quarter earnings report on Aug. 4, followed by an analyst call at 10:00 a.m. EDT. The call is expected to focus on the Seagen pipeline, ADC strategy, and the financial implications of the recent trial setback. The company also faces a CFO transition, with Dave Denton departing Aug. 15 and Cecile Guegan serving as interim CFO.
Risks remain elevated. Should the Keytruda combo study fail or the second-line signal weaken upon full data disclosure, Pfizer may need to rely more heavily on other oncology and obesity drugs while navigating generic competition, declining COVID product sales, and leadership changes.
